Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France
These results emphasize the urgency to treat MM patients with the best and tailored treatment strategy available, for all MM patients beneficiating or not from a transplant in frontline therapy. Further studies will be needed to assess the impact of new therapeutic options in real life.
Authors
- Marie Pierrès
- F. Raguideau (ORCID: https://orcid.org/0000-0002-7611-371X)
- Cyrille Touzeau (ORCID: https://orcid.org/0000-0003-0275-2575)
- Martin Prodel
- Aurore Perrot (ORCID: https://orcid.org/0000-0003-0131-8689)
- Hélène Denis (ORCID: https://orcid.org/0000-0002-8881-4679)
- Matthieu Javelot
Institutions
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Janssen (France) (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1016/j.clml.2025.03.004
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- Amgen
- Sanofi
- Celgene
- Conservatoire National des Arts et Métiers
- Cilag